(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Building Tough Connections: Individual Bits of knowledge on Association - 2Cocoa Prices Undercut Amid the Prospects of Abundant Supplies
- 3Wait, it's 'Harry Potter and the Philosopher's Stone'? Why the new HBO series name is significant to Americans
- 4Zelensky sees win for Ukraine as EU finally reaches funding deal
- 5Dominating the Art of Composing: Creator Bits of knowledge
- 7 Strange Apparatuses to Make Your Party Stick Out!
- Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- Volcanic eruption led to the Black Death, new research suggests
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- Worldwide Objections Ideal For A Golf Outing
- Doctored NXT Summit footage falsely portrays Modi as declaring war on Iran and Pakistan
- New dinosaur tracks in Italy illustrate herds moving in unison
- CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
- Most loved Seared Chicken: Which Chain Rules?
